{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:52:52Z","timestamp":1787014372606,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,12,10]],"date-time":"2017-12-10T00:00:00Z","timestamp":1512864000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"John Burge Trust"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9\u2010month course of isoniazid (9H). A 3\u2010month course of weekly isoniazid and rifapentine (3HP) has been shown to be as effective as 9 months of daily isoniazid, and associated with less hepatotoxicity; however, rifapentine is not currently available in Australia. Introduction of this regimen would have apparent advantages for people with LTBI in Victoria by safely shortening duration of LTBI therapy. However, the cost benefit of this new therapeutic approach is uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Cost\u2010analysis of standard and short\u2010course therapy for LTBI in an Australian context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single\u2010centre randomised controlled trial conducted between December 2013\u2010March 2016. Participants underwent 1:1 randomisation to either a 9\u2010month course of daily isoniazid or a 12\u2010week course of weekly isoniazid and rifapentine. The primary outcome measure was total healthcare system costs (in Australian dollars; AUD) per completed course of LTBI therapy. Secondary cost analyses were performed to consider varying assumptions regarding commercial cost of rifapentine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 34 of 40 (85%) participants in the 9H group and 36\/40 (90%) in the 3HR group completed therapy. One patient in the 3HP group was hospitalised for a febrile illness; no hospitalisations were recorded in the 9H group. The cost per completed course of 9H was 601 AUD, while that of 3HP was significantly lower at 511 AUD (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides cost analysis evidence to support the use of 3HP for the treatment of LTBI in Australia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.13601","type":"journal-article","created":{"date-parts":[[2017,12,10]],"date-time":"2017-12-10T18:00:35Z","timestamp":1512928835000},"page":"1433-1436","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["<scp>SIRCLE<\/scp>\n                    : a randomised controlled cost comparison of self\u2010administered short\u2010course isoniazid and rifapentine for cost\u2010effective latent tuberculosis eradication"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9214-6431","authenticated-orcid":false,"given":"Justin T.","family":"Denholm","sequence":"first","affiliation":[{"name":"Victorian Tuberculosis Program Melbourne Health  Melbourne Victoria Australia"},{"name":"Victorian Infectious Diseases Service Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Microbiology and Immunology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"McBryde","sequence":"additional","affiliation":[{"name":"Division of Tropical Health and Medicine James Cook University  Townsville Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Eisen","sequence":"additional","affiliation":[{"name":"Division of Tropical Health and Medicine James Cook University  Townsville Queensland Australia"},{"name":"Townsville Hospital  Townsville Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Street","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Service Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Matchett","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Service Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Shultz","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Service Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Biggs","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Service Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Leder","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Service Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"School of Public Health and Preventive Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.017"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200408193510823"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja12.10035"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/284028"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_2_6_8_1","first-page":"1650","article-title":"Recommendations for use of an isoniazid\u2010rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","year":"2011","journal-title":"MMWR"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01245-2015"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0423"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0052"},{"key":"e_1_2_6_12_1","volume-title":"Management of tuberculosis","author":"Street AS","year":"2012"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12290"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.5588\/pha.14.0089"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S68837"},{"key":"e_1_2_6_16_1","volume-title":"Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA","author":"Belknap R","year":"2015"}],"updated-by":[{"DOI":"10.1111\/imj.13763","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000}}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.13601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.13601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T12:54:06Z","timestamp":1695819246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.13601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/imj.13601"],"URL":"https:\/\/doi.org\/10.1111\/imj.13601","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"2016-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}